Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Mesothelioma, Malignant 1Lung Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × alanosine × Clear all
NCT00062283 2013-06-26

Alanosine in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡